Unicycive Therapeutics reports 2025 results, business update

Unicycive Therapeutics has announced its full-year financial results for 2025 and provided a comprehensive business update. A key highlight is the ongoing review by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) for oxylanthanum carbonate (OLC). This regulatory step is critical for the potential approval and commercialization of the drug. The company's update likely covers progress on its drug development pipeline, financial standing, and strategic outlook for the coming year, offering insights into its future trajectory.